US Lymphedema Treatment Market is expected to reach US$ 8,320.07 million by 2028

Publisher: The Insight Partners

According to our new research study on “US Lymphedema Treatment Market Forecast to 2028 – COVID-19 Impact and Country Analysis – by Condition Type, Treatment Type, End User, and Geography,” the market is expected to grow from US$ 5,185.98 million in 2022 to US$ 8,320.07 million by 2028; it is estimated to record a CAGR 8.2% during 2023–2028. Factors like the rising incidence of lymphedema cases and increasing healthcare services and lymphedema management programs are driving the US lymphedema treatment market growth. However, a lack of awareness and skilled professionals restrict the growth of the market.

Lymphedema is a condition in which the body enlarges abnormally due to the lymphostasis caused by lymphatic system dysfunction. It most commonly affects the lower extremity (90%), upper extremity (10%), and genitalia (1%).

Based on treatment type, the US lymphedema treatment market is segmented into laser therapy, compression devices and bandaging, drug therapy, physiological procedures, debulking procedures, and others. The physiological procedures segment is further sub-segmented into lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT). Similarly, the debulking procedures segment is subdivided into surgical debulking, liposuction, and others. The compression devices and bandaging segment held the largest share of the market in 2022. The physiological procedure segment is anticipated to register the highest CAGR during the forecast period mainly due to the treatment availability through LVA and VLNT performed on lymphedema patients. Two main physiologic interventions are currently incorporated to treat lymphedema. The primary intervention creates a shunt (a hole or a small passage to facilitate movement) between the congested lymphatic channels with the venous system close to the location of lymphatic obstruction. The other physiologic intervention incorporates vascularized soft tissue flaps that frequently include vascularized lymph nodes to the affected lymphatic extremity.

COVID-19 Pandemic Impact the US Lymphedema Treatment Market Growth

The prolonged shut-in situation is devastating news for countless industries impacted by business closures, but there are bright spots for sectors that have thrived amid the global health crisis so far. Lymphedema treatment is one sector that has shown remarkable stamina.

Lymphedema patients' health care was greatly affected by the COVID-19 lockdown not only from a medical perspective but also from a psychosocial perspective. Identifying and dealing with all these implications properly is crucial to avoiding concerns and consequences resulting from future pandemic lockdowns. To meet the needs of patients suffering from lymphedema, lymphedema services should be well prepared to be delivered virtually, enabling effective care, and shared knowledge.

US Lymphedema Treatment Market: Competitive Landscape and Key Developments

Biocompression Systems, Tactile Medical, Essity AB, Lohmann & Rauscher GmbH & Co. KG, Sigvaris Group, ThermoTek Inc., Huntleigh Healthcare Limited, 3M Co, AIROS Medical, and Paul Hartmann AG are among the major players in the US lymphedema treatment market. Leading players adopt strategies such as the launch of new products, expansion and diversification of their market presence, and expansion of new customer base for tapping prevailing business opportunities.

• In April 2023, AIROS Medical received FDA clearance to market new peristaltic pneumatic compression device, truncal garments for lymphedema treatment. The clearance also allows AIROS to provide larger compression therapy garments including lower truncal garments to treat abdominal swelling.
• In October 2021, HARTMANN USA announced the immediate of TwoPress® 2 Lite. TwoPress® 2 Lite is an extension of our two-layer compression systems. Along with TwoPress® 2, both systems offer simple and convenient application that help boost clinician and patient confidence.
• In May 2020, AIROS Medical launched new compression therapy device and garment system to treat breast cancer patients. AIROS received US Food and Drug Administration (FDA) 510(k) clearance to market its updated AIROS 6 sequential compression device and related accessory garments, including the Arm Plus garment that can be prescribed by a physician to treat lymphedema in the arm, shoulder, chest, and back.
• In December 2020, Tactile Medical received 510(k) clearance for Flexitouch Plus system which indicates phlebolymphedema and lipedema.

The report segments the US lymphedema treatment market as follows:

The US lymphedema treatment market is segmented on the basis of condition type, treatment type, and others. Based on the condition type, the market is segmented into primary lymphedema and secondary lymphedema. Based on treatment type, the US lymphedema treatment market is segmented into laser therapy, compression devices & bandaging, drug therapy, physiological procedures, debulking procedures, and others. By end user, the US lymphedema treatment market is segmented into hospitals, clinics, clinical research organizations, and others.

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com